Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH)

FairStock Score: 95/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $91 million in annual free cash flow (4.3% yield on market cap)
• High return on equity of 59.9% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.13, providing financial flexibility
• Altman Z-Score of 7.1 confirms minimal bankruptcy risk and strong solvency
• Superior net profit margin of 74.5% indicating pricing power and operational efficiency

AI Analysis

Aurinia Pharmaceuticals Inc Ordinary Shares is a small-cap healthcare company valued at $2.1 billion. The business generates $283 million in annual revenue with a 74.5% net margin and $91 million in free cash flow. From a quality standpoint, Aurinia shows Altman Z-Score of 7.1 confirms fortress-level solvency and extraordinary 60% return on equity. On valuation, the stock is deeply undervalued on a P/E basis at 7.8x, with trades above its Graham Number with a negative 14% margin. Growth dynamics show revenue growing at 28.8% and profit growth of 14651.1%. Our composite FairStock Score of 95/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

Aurinia's 29% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $91 million in annual free cash flow (4.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer